Sirius Therapeutics Reports Phase I Clinical Data for SRSD107
Sirius Therapeutics has recently unveiled promising preliminary data from its Phase 1 clinical trial of SRSD107, a cutting-edge siRNA therapeutic. This innovative treatment is focusing on preventing and addressing thromboembolic disorders, including myocardial infarction and ischemic stroke.
Safety and Effectiveness of SRSD107
The Phase 1 trial showcases SRSD107's ability to inhibit Factor XI (FXI), a crucial protein in the coagulation pathway that is associated with thrombosis. According to Dr. Patrick Yue, the Chief Medical Officer of Sirius, the treatment was found to be safe and well-tolerated among the 40 healthy subjects involved in the single-site study.
Clinical Trial Highlights
During the trial, subjects received eight doses of SRSD107 in a randomized, double-blind setup, either receiving the treatment or a placebo. Notably, the trial reported significant improvements in pharmacodynamic (PD) biomarkers; FXI levels dropped by over 90%, while an aPTT increase of more than 100% demonstrated potent anticoagulation effects.
Long-Term Benefits of SRSD107
The pharmacodynamic effects displayed by SRSD107 are remarkable, with sustained levels of FXI antigen and activity remaining suppressed for over 16 weeks post-dosing. These findings are a testament to the longevity and effectiveness of the drug, providing a potential new pathway for treating various thromboembolic conditions.
Expert Insights on SRSD107
Dr. Qunsheng Ji, the Chief Executive Officer of Sirius Therapeutics, emphasized the significance of these findings, particularly in light of their presentation at a national meeting of hematology experts. This event underscores the company's commitment to delivering innovative solutions for thromboembolic disorders.
Understanding Thromboembolic Disorders
Thromboembolic disorders, including myocardial infarction, are a leading cause of mortality worldwide. Studies indicate that these conditions contribute to approximately one in every four deaths globally. The urgency for effective treatments is critical, making the development of SRSD107 a potentially transformative approach.
The Mechanism of SRSD107
SRSD107, a novel double-stranded small interfering ribonucleic acid (siRNA), specifically targets FXI mRNA to inhibit its protein expression. This strategic blockage effectively disrupts the intrinsic coagulation pathway, offering a promising anticoagulant and anti-thrombotic effect with the potential for administration once or twice a year.
About Sirius Therapeutics
Sirius Therapeutics is a pioneering biotech firm in the clinical stage, focusing on developing siRNA therapies for a global market. Founded in 2021, Sirius aims to translate advanced siRNA technology into impactful treatments for patients with chronic health challenges. Their leading products, SRSD107 and SRSD101, target thromboembolic disorders and dyslipidemia, respectively.
The company has successfully raised approximately US$100 million in funding from notable investors, including OrbiMed and Creacion Ventures. Additionally, it has established research centers in the United States and China, underscoring its commitment to medical innovation and patient care.
Frequently Asked Questions
What is SRSD107 and what conditions does it target?
SRSD107 is an innovative siRNA therapeutic from Sirius Therapeutics that targets thromboembolic disorders, such as myocardial infarction and ischemic stroke.
What were the results of the Phase 1 clinical trial?
The Phase 1 trial indicated that SRSD107 is safe and well-tolerated, with significant reductions in FXI levels and prolonged anticoagulation effects observed in healthy subjects.
How does SRSD107 work?
SRSD107 functions by inhibiting the expression of the coagulation factor XI protein, affecting the blood clotting pathway and offering anticoagulation benefits.
What are thromboembolic disorders?
Thromboembolic disorders involve abnormal blood clot formation, which can lead to severe conditions, including heart attacks and strokes, and are a major cause of global mortality.
What future steps is Sirius Therapeutics taking?
Sirius Therapeutics plans to advance SRSD107 into Phase 2 clinical studies following the encouraging results obtained in Phase 1, continuing its mission to provide innovative medical solutions.
